CERE

Cerevel Therapeutics Holdings, Inc.

41.83 USD
-0.02 (-0.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cerevel Therapeutics Holdings, Inc. stock is down -0.52% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 12 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 May 15:09 20 Dec, 2024 35.00 PUT 500 7883
30 May 15:03 20 Dec, 2024 35.00 PUT 500 8397
03 Jun 15:17 18 Oct, 2024 42.50 CALL 300 2
03 Jun 18:43 18 Oct, 2024 42.50 CALL 1000 2
04 Jun 17:28 19 Jul, 2024 40.00 PUT 400 3
06 Jun 15:19 17 Jan, 2025 35.00 PUT 2850 45
11 Jun 19:03 18 Oct, 2024 37.50 PUT 490 234
13 Jun 14:42 18 Oct, 2024 42.50 CALL 500 3865
13 Jun 15:15 18 Oct, 2024 42.50 CALL 455 3865
14 Jun 19:23 20 Dec, 2024 45.00 CALL 5002 15736

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist, and CVL-871, which is in Phase 2a clinical trial to treat dementia-related apathy.